Disease · MONDO_0005393
Comparisons in its trials27
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 27
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Febuxostat vs Dotinurad: deaths from any cause | 0 of 225 | 0 of 223 | 448 | NCT05007392 | Trial comparisons |
| Febuxostat vs Dotinurad: serious adverse events | 4 of 225 | 3 of 223 | 448 | NCT05007392 | Trial comparisons |
| Low-dose Colchicine vs Naproxen: deaths from any cause | 0 of 199 | 0 of 200 | 399 | NCT01994226 | Trial comparisons |
| Low-dose Colchicine vs Naproxen: serious adverse events | 1 of 199 | 2 of 200 | 399 | NCT01994226 | Trial comparisons |
| Febuxostat 40 mg or 80 mg vs Placebo: serious adverse events | 13 of 157 | 11 of 157 | 314 | NCT01078389 | Trial comparisons |
| Lesinurad 400 mg vs Placebo: serious adverse events | 9 of 107 | 4 of 107 | 214 | NCT01508702 | Trial comparisons |
| Lesinurad 200 mg + Febuxostat 80 mg vs Lesinurad 400 mg + Febuxostat 80 mg: deaths from any cause | 1 of 97 | 0 of 99 | 196 | NCT01808144 | Trial comparisons |
| Lesinurad 200 mg + Febuxostat 80 mg vs Lesinurad 400 mg + Febuxostat 80 mg: serious adverse events | 16 of 97 | 19 of 99 | 196 | NCT01808144 | Trial comparisons |
| Febuxostat 80/120 mg/Day vs Allopurinol 100 up to 600 mg/Day: deaths from any cause | 0 of 98 | 0 of 98 | 196 | NCT02500641 | Trial comparisons |
| Febuxostat 80/120 mg/Day vs Allopurinol 100 up to 600 mg/Day: serious adverse events | 10 of 98 | 8 of 98 | 196 | NCT02500641 | Trial comparisons |
| SEL-212 vs KRYSTEXXA: Number of Participants With SUA Reduction of < 6 mg/dL for 100% of the Time During Month 6 | 38 of 83 | 36 of 87 | 170 | NCT03905512 | Trial comparisons |
| SEL-212 vs KRYSTEXXA: Number of Participants With SUA Reduction of < 6 mg/dL for At Least 80% of the Time During Month 6 | 45 of 83 | 41 of 87 | 170 | NCT03905512 | Trial comparisons |
| SEL-212 vs KRYSTEXXA: Number of Participants With Serum Uric Acid (SUA) Reduction of < 6 mg/dL for at Least 80% of the Time | 44 of 83 | 40 of 87 | 170 | NCT03905512 | Trial comparisons |
| SEL-212 vs KRYSTEXXA: deaths from any cause | 0 of 83 | 0 of 87 | 170 | NCT03905512 | Trial comparisons |
| SEL-212 vs KRYSTEXXA: serious adverse events | 7 of 83 | 8 of 87 | 170 | NCT03905512 | Trial comparisons |
| AC-201 vs Placebo: Proportion of Subjects Achieving Serum Uric Acid Concentration <6.0 mg/dL | 43 of 67 | 33 of 60 | 127 | NCT02287818 | Trial comparisons |
| AC-201 vs Placebo: deaths from any cause | 0 of 67 | 0 of 60 | 127 | NCT02287818 | Trial comparisons |
| AC-201 vs Placebo: serious adverse events | 0 of 67 | 0 of 60 | 127 | NCT02287818 | Trial comparisons |
| Cohort 1 vs Cohort 2: deaths from any cause | 0 of 20 | 0 of 21 | 41 | NCT02498652 | Trial comparisons |
| Cohort 1 vs Cohort 2: serious adverse events | 1 of 20 | 0 of 21 | 41 | NCT02498652 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005393/comparisons